Summary
The effects of sera and of platelet-poor plasma from patients with scleroderma on endothelial cell survival in vitro were studied. The survival ratio of rat heart endothelial cells was studied both in 10% test serum and in 10% platelet-poor plasma. Sera from patients with scleroderma decreased the survival ratio significantly when compared with sera from normal controls. In contrast, there was no significant difference between platelet-poor plasma from patients with scleroderma and that from normal controls. Our data indicate that platelets in the patients with scleroderma may cause vascular damage by affecting endothelial cell survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barnett AJ (1974) Scleroderma. Charles C. Thomas, Springfield, Ill., p 73
Cohen S, Johnson AR, Hurd E (1983) Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum 26:170–178
DiCorleto PE, dela Motte CA (1985) Characterization of the adhesion of the human monocytic cell line U937 to cultured endothelial cell. J Clin Invest 75:1153–1161
Etoh T, Takehara K, Igarashi A, Ishibashi Y (1989) The effects of various growth factors on endothelial cell survival in vitro. Biochem Biophys Res Commun 162:1010–1016
Falanga V, Suam LT, Stephanie PA, Alstadt MS, Roberts AB, Sporn MB (1987) Transforming growth factor-beta: Selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J Invest Dermatol 89:100–104
Fleishmajer R, Perish JS, Shaw KU, Prozzi DJ (1976) Skin capillary changes in early systemic scleroderma. Arch Dermatol 112:1553–1557
Igarashi A, Takehara K, Soma Y, Kikuchi K, Ishibashi Y (1989) Mitogenic activities for skin fibroblasts in the sera from untreated scleroderma patients at early stages. Arch Dermatol Res 281:383–386
Ignotz RA, Massague J (1985) Transforming growth factor-Β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337–4345
Kahaleh MB, LeRoy EC (1983) Endothelial cell injury in scleroderma. A protease mechanism. J Lab Clin Med 101:553–560
Kahaleh MB, Sherer GK, LeRoy (1979) Endothelial cell injury in scleroderma. J Exp Med 149:1326–1335
Leof EB, Proper JA, Goustin AS, Shipley GD, DiCorleto PE, Moses HL (1986) Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor b: a proposed model for indirect mitogenesis involving automne activity. Proc Natl Acad Sci USA 83:2453–2457
LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM (1989) A strategy for scleroderma (systemic sclerosis): is transforming growth factor beta the answer? Arthritis Rheum 32:817–825
Marks RM, Czerniecki M, Andrews BS, Penny R (1988) The effects of scleroderma serum on human microvascular endothelial cells. Arthritis Rheum 31:1524–1534
Miyazono K, Okabe T, Urabe A, Yamanaka M, Takaku F (1985) A platelet factor that stimulates the proliferation of vascular endothelial cells. Biochem Biophys Res Commun 126:83–88
Moroi Y, Peebies C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631
Norton WL, Nardo JM (1970) Vascular disease in progressive systemic sclerosis. Ann Intern Med 73:317–324
Norton WL, Hurd ER, Lewis DC, Ziff M (1968) Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: quantitative study of the microvascvlar bed. J Lab ClinMed 71:919–933
O'Connor-McCourt MD, Wakefield LM (1987) Latent transforming growth factor-Β in serum. A specific complex with α2-macroglobulin. J Biol Chem 262:14090–14099
Oka Y, Orth DN (1983) Human plasma epidermal growth factor-Β urogastrone is associated with blood platelets. J Clin Invest 72:249–259
Penning CA, Cunningham J, French MAH, Harrison G, Rowell NR, Hughes P (1984) Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 58:548–556
Roberts AB, Sporn MB, Associan RH, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS (1986) Transforming growth factor type Β; rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171
Shanahan WR, Korn JH (1982) Cytotoxic activity of sera from scleroderma and other connective tissue disease. Lack of cellular and disease specificity. Arthritis Rheum 25:391–1395
Soma Y, Grotendorst GR (1989) TGF-Β stimulates primary human skin fibroblast DNA-synthesis via an autocrine production of PDGF related peptides. J Cell Physiol 140:246–253
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum23:581–590
Takehara K, Moroi Y, Ishibashi Y (1985) Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol 112:23–33
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Etoh, T., Igarashi, A., Iozumi, K. et al. The effects of scleroderma sera on endothelial cell survival in vitro. Arch Dermatol Res 282, 516–519 (1990). https://doi.org/10.1007/BF00371946
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00371946